Upgrades

Valeant Pharmaceuticals (VRX) Upgraded by Zacks to OUTPERFORM

Zacks Investment Research upgraded shares of Valeant Pharmaceuticals (VRX) from UNDERPERFORM to OUTPERFORM on October 31, 2014, with a target price of $158.00. Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day . To get a free copy of the research report on Valeant Pharmaceuticals (VRX), click here […]

Stock Analysts

Merge Healthcare Q3 Revenues Top Estimates, Earnings Up

Merge Healthcare Incorporated ( MRGE ) reported third-quarter 2014 adjusted net income per share of 4 cents, an improvement from a penny earned in the year-ago quarter. Reported net income of $1.7 million or loss of 2 cents per share in the third quarter compared favorably with the year-ago net loss of $4.1 million or loss of 4 cents per share. […]

The Motley Fool Video

Interview with Reid Hoffman

[youtube ncSQu9x6lIg] Investing made simple: The Motley Fool’s essential guide to investing is now available to the public, free of cost, at http://bit.ly/1pCQeNI. This resource was designed to cover everything that new investors need to know to get started today. […]

Stock Analysts

Tenneco Beats Q3 Earnings Yet Down on Lukewarm Q4 View

Tenneco Inc. ’s ( TEN ) shares have lost 5.7% in the last four trading sessions after the company revealed lukewarm guidance for the fourth quarter along with its third-quarter 2014 financial results. The company reported adjusted earnings per share of $1.25 in the quarter, which beat the Zacks Consensus Estimate of $1.08. […]